NCT06149286 2026-04-13
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
17 trialsNCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT04998669 2026-03-23
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
University of Miami
Phase 2 Recruiting
NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04224493 2026-03-02
SYMPHONY-1
Ipsen
Phase 3 Recruiting
NCT06563596 2026-02-19
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06350318 2026-02-05
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04669171 2026-01-30
SIDNEY
Enterome
Phase 1/2 Recruiting
NCT05783609 2025-12-23
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06911502 2025-12-05
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT06792825 2025-08-12
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06704555 2024-11-26
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06471738 2024-07-18
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Chinese PLA General Hospital
Phase 2 Recruiting
NCT05848765 2023-11-29
REFRACT
University of Birmingham
Phase 2 Recruiting